Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma
Papaleo, Natalia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Climent, Fina (Hospital Universitari de Bellvitge)
Tapia, Gustavo (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques)
Luizaga Velasco, Luis (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Azcarate, Juan (Hospital Universitari de Bellvitge)
Bosch-Schips, Jan (Hospital Universitari de Bellvitge)
Muñoz-Mármol, Ana Maria (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques)
Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques)
Lome-Maldonado, Carmen (Institut Hospital del Mar d'Investigacions Mèdiques)
Vázquez, Ivonne (Institut Hospital del Mar d'Investigacions Mèdiques)
Colomo, Luis (Institut Hospital del Mar d'Investigacions Mèdiques)
Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques

Date:	2024
Abstract:	Aggressive large B-cell lymphomas (aLBCL) include a heterogeneous group of lymphomas with diverse biological features. One of the approaches to the diagnosis of aLBCL is based on the identification of MYC rearrangements (MYC-R), in addition to BCL2 and BCL6 rearrangements by genetic techniques, mainly fluorescent in situ hybridization (FISH). Because of the low incidence of MYC-R, the identification of useful immunohistochemistry markers to select cases for MYC FISH testing may be useful in daily practice. In a previous work, we identified a strong association between the profile CD10 positive/LMO2 negative expression and the presence of MYC-R in aLBCL and obtained good intralaboratory reproducibility. In this study, we wanted to evaluate external reproducibility. To evaluate whether LMO2 can be a reproducible marker between observers 50 aLBCL cases were circulated among 7 hematopathologists of 5 hospitals. Fleiss' kappa index for LMO2 and MYC were 0. 87 and 0. 70, respectively, indicating high agreement between observers. In addition, during 2021-2022, the enrolled centers included LMO2 in their diagnostic panels to evaluate prospectively the utility of the marker, and 213 cases were analyzed. Comparing LMO2 with MYC, the group of CD10 positive cases showed higher specificity (86% vs 79%), positive predictive value (66% vs 58%), likelihood positive value (5. 47 vs 3. 78), and accuracy (83% vs 79%), whereas the negative predictive values remained similar (90% vs 91%). These findings place LMO2 as a useful and reproducible marker to screen MYC-R in aLBCL.
Grants:	Instituto de Salud Carlos III PI17/313
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Lymphomas ; Large B-cell lymphoma ; MYC, LMO2, FISH
Published in:	Virchows Archiv, Vol. 485 Num. 2 (August 2024) , p. 307-314, ISSN 1432-2307

DOI: 10.1007/s00428-023-03584-9
PMID: 37368083

8 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles